Organ Preservation Market-Forecast till 2027

List of Tables

Market Overview

As per the MRFR analysis, the global organ preservation market is anticipated to witness a healthy market expansion of 6.48% during the review period to surpass USD 304.68 million by the end of 2027.

Organ preservation is the stock line for organ transplantation. At present, the pancreas, liver, and kidney can be safeguarded for as long as two days by flushing the organs with the University of Wisconsin (UW) organ preservation arrangement as well as putting away them at hypothermia (0-5 degrees C). The UW arrangement is viable in the light of the fact that it utilized a few cell impermeant specialists like raffinose, lactobionic corrosive, and hydroxyethyl starch which decrease the phones from aggravation during cold ischemic stockpiling. The rising number of organ relocation techniques goes about as a significant driver in the worldwide organ preservation market from 2021 to 2027. In any case, the significant expense related to organ transplantation hampers the development of the organ preservation market during the gauge time frame. Expanding government drives connected with organ transfers and organ gifts are supposed to set out freedom in the worldwide organ preservation market.

Segment Overview

The global organ preservation market is categorized among solution, preservation techniques, organ type, and end-user.

The Solution segment is further classified into the University of Wisconsin Solution, Custodial HTK, Collins Solution, Celsior Solution, Perfadex, and Citrate Solution.

The preservation techniques segment is divided into static cold storage and dynamic cold storage. Dynamic cold storage is further divided into hypothermic machine perfusion, normothermic machine perfusion, and oxygen per sufflation.

Based on the organ type, the market is divided into heart, kidney, lungs, liver, and others. The end-user segment divides the market into organ banks, hospitals & clinics, and others.

Regional Analysis

The Americas is likely to lead the global organ preservation market owing to the largest market share of 45.7% during the review period. The regional market growth is attributed to the growing number of organ transplant procedures, growing incidences of multiple organ failure, and rising geriatric failure. Americas is classified into North America and Latin America. The North American market is spread across the US and Canada.

Europe is the second-biggest market and holds a solid offer in the worldwide organ protection market. The European market is supposed to develop at a tough rate during the conjecture time frame because of cutting-edge treatment offices and rising instances of greasy liver sickness.

Asia-Pacific is assessed to be the quickest developing business sector attributable to the creation of medical care foundations and expanding extra cash in agricultural nations like China and India. The Middle East and Africa is supposed to observe consistent development because of an absence of mindfulness with respect to organ gift, restricted admittance, and the exorbitance of treatment offices among the populace.

Major Players

The prominent players operating in the global organ preservation are TransMedics Group, Inc (US), Inc (US), Shanghai Genext Medical Technology Co., Ltd (China), 21st Century Medicine (US), Bristol Myers Squibb (US), Artivion, Inc (US), BioLife Solutions, Paragonix Technologies Inc (US), Xvivo Perfusion AB (US), Accord Healthcare Limited (UK), Franz Kohler Chemie GmbH (Germany), and Waters Medical Systems (US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/4615-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 16

1.1 MARKET SYNOPSIS 16

2 MARKET INTRODUCTION 17

2.1 SCOPE OF THE STUDY 17
2.2 RESEARCH OBJECTIVE 17
2.3 LIST OF ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY 19

3.1 DATA MINING 19
3.2 SECONDARY RESEARCH 20
3.3 PRIMARY RESEARCH 21
- 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21
- 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 22
3.4 FORECASTING TECHNIQUES 22
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23
- 3.5.1 BOTTOM-UP APPROACH 24
- 3.5.2 TOP-DOWN APPROACH 25
3.6 DATA TRIANGULATION 25
3.7 VALIDATION 25

4 MARKET DYNAMICS 26

4.1 OVERVIEW 26
4.2 DRIVERS 27
- 4.2.1 INCREASING FOCUS OF ORGAN PRESERVATION COMPANIES ON BRAND PROTECTION 27
- 4.2.2 RISING NUMBER OF ORGAN TRANSPLANT PROCEDURES 27
- 4.2.3 RISING INSTANCES OF MULTIPLE ORGAN FAILURE 27
4.3 RESTRAINT 28
- 4.3.1 HIGH COST ASSOCIATED WITH ORGAN TRANSPLANTATION 28
4.4 OPPORTUNITY 29
- 4.4.1 INCREASING GOVERNMENT INITIATIVES RELATED TO ORGAN TRANSPLANT AND ORGAN DONATION 29

5 MARKET FACTOR ANALYSIS 30

5.1 VALUE CHAIN ANALYSIS 30
- 5.1.1 R&D 31
- 5.1.2 MANUFACTURING 31
- 5.1.3 DISTRIBUTION AND SALES 31
- 5.1.4 POST-SALES MONITORING 31
5.2 PORTER'S FIVE FORCES MODEL 32
- 5.2.1 BARGAINING POWER OF SUPPLIERS 32
- 5.2.2 BARGAINING POWER OF BUYERS 33
- 5.2.3 THREAT OF NEW ENTRANTS 33
- 5.2.4 THREAT OF SUBSTITUTES 33
- 5.2.5 INTENSITY OF RIVALRY 33
5.3 IMPACT OF COVID-19 ON ORGAN PRESERVATION MARKET 33
- 5.3.1 OVERVIEW 33
- 5.3.2 IMPACT ON SUPPLY CHAIN 33
- 5.3.3 IMPACT ON DEMAND FOR ORGAN PRESERVATION SOLUTIONS 34

6 GLOBAL ORGAN PRESERVATION MARKET, BY SOLUTION 35

6.1 OVERVIEW 35
6.2 UNIVERSITY OF WISCONSIN SOLUTION 36
6.3 CUSTODIOL HTK 36
6.4 COLLINS SOLUTION 37
6.5 CELSIOR SOLUTION 38
6.6 PERFADEX 39
6.7 CITRATE SOLUTION 40

7 GLOBAL ORGAN PRESERVATION MARKET, BY PRESERVATION TECHNIQUES 41

7.1 OVERVIEW 41
7.2 STATIC COLD STORAGE (SCS) TECHNIQUE 42
7.3 DYNAMIC COLD STORAGE 42
- 7.3.1 HYPOTHERMIC MACHINE PERFUSION 43
- 7.3.2 NORMOTHERMIC MACHINE PERFUSION 44
- 7.3.3 OXYGEN PERSUFFLATION 44

8 GLOBAL ORGAN PRESERVATION MARKET, BY ORGAN TYPE 45

8.1 OVERVIEW 45
8.2 KIDNEY 46
8.3 LIVER 46
8.4 HEART 47
8.5 LUNGS 48
8.6 OTHERS 48

9 GLOBAL ORGAN PRESERVATION MARKET, BY END USER 49

9.1 OVERVIEW 49
9.2 HOSPITALS & CLINICS 50
9.3 ORGAN BANKS 50
9.4 OTHERS 51

10 GLOBAL ORGAN PRESERVATION MARKET, BY REGION 52

10.1 OVERVIEW 52
10.2 AMERICAS 54
- 10.2.1 NORTH AMERICA 57
  - 10.2.1.1 US 59
  - 10.2.1.2 CANADA 61
- 10.2.2 LATIN AMERICA 63
10.3 EUROPE 65
- 10.3.1 WESTERN EUROPE 67
  - 10.3.1.1 SPAIN 70
  - 10.3.1.2 FRANCE 71
  - 10.3.1.3 UK 73
  - 10.3.1.4 ITALY 75
  - 10.3.1.5 GERMANY 76
  - 10.3.1.6 REST OF WESTERN EUROPE 78
- 10.3.2 EASTERN EUROPE 80
10.4 ASIA PACIFIC 82
- 10.4.1 CHINA 85
- 10.4.2 INDIA 86
- 10.4.3 AUSTRALIA 88
- 10.4.4 SOUTH KOREA 90
- 10.4.5 JAPAN 91
- 10.4.6 REST OF ASIA PACIFIC 93
10.5 MIDDLE EAST & AFRICA 95
- 10.5.1 MIDDLE EAST 97
- 10.5.2 AFRICA 99

11 COMPETITIVE LANDSCAPE 101

11.1 OVERVIEW 101
11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ORGAN PRESERVATION

MARKET 104

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 105
- 11.6.1 PRODUCT APPROVAL 105
- 11.6.2 ACQUISITION 105
- 11.6.3 PRODUCT LAUNCH 106

11.7 MAJOR PLAYERS FINANCIAL MATRIX 106
- 11.7.1 SALES (USD MILLION), 2020 106
- 11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020 106

12 COMPANY PROFILES 107

12.1 TRANSMEDICS GROUP, INC. 107
- 12.1.1 COMPANY OVERVIEW 107
- 12.1.2 FINANCIAL OVERVIEW 108
- 12.1.3 PRODUCTS/SERVICES OFFERED 108
- 12.1.4 KEY DEVELOPMENTS 109
- 12.1.5 SWOT ANALYSIS 109
- 12.1.6 KEY STRATEGIES 109
12.2 BRISTOL-MYERS SQUIBB COMPANY 110
- 12.2.1 COMPANY OVERVIEW 110
- 12.2.2 FINANCIAL OVERVIEW 110
- 12.2.3 PRODUCTS/SERVICES OFFERED 111
- 12.2.4 KEY DEVELOPMENTS 111
- 12.2.5 SWOT ANALYSIS 111
- 12.2.6 KEY STRATEGIES 111
12.3 CRYOLIFE, INC. 112
- 12.3.1 COMPANY OVERVIEW 112
- 12.3.2 FINANCIAL OVERVIEW 112
- 12.3.3 PRODUCTS/SERVICES OFFERED 113
- 12.3.4 KEY DEVELOPMENTS 113
- 12.3.5 SWOT ANALYSIS 113
- 12.3.6 KEY STRATEGIES 113
12.4 XVIVO PERFUSION AB 114
- 12.4.1 COMPANY OVERVIEW 114
- 12.4.2 FINANCIAL OVERVIEW 114
- 12.4.3 PRODUCTS/SERVICES OFFERED 115
- 12.4.4 KEY DEVELOPMENTS 115
- 12.4.5 SWOT ANALYSIS 116
- 12.4.6 KEY STRATEGIES 116
12.5 ACCORD HEALTHCARE 117
- 12.5.1 COMPANY OVERVIEW 117
- 12.5.2 FINANCIAL OVERVIEW 117
- 12.5.3 PRODUCTS/SERVICES OFFERED 117
- 12.5.4 KEY DEVELOPMENTS 117
- 12.5.5 SWOT ANALYSIS 118
- 12.5.6 KEY STRATEGIES 118
12.6 DR. FRANZ KOEHLER CHEMIE GMBH 119
- 12.6.1 COMPANY OVERVIEW 119
- 12.6.2 FINANCIAL OVERVIEW 119
- 12.6.3 PRODUCTS/SERVICES OFFERED 119
- 12.6.4 KEY DEVELOPMENTS 119
- 12.6.5 SWOT ANALYSIS 120
- 12.6.6 KEY STRATEGIES 120
12.7 21ST CENTURY MEDICINE 121
- 12.7.1 COMPANY OVERVIEW 121
- 12.7.2 FINANCIAL OVERVIEW 121
- 12.7.3 PRODUCTS/SERVICES OFFERED 121
- 12.7.4 KEY DEVELOPMENTS 121
- 12.7.5 SWOT ANALYSIS 122
- 12.7.6 KEY STRATEGIES 122
12.8 BIOLIFE SOLUTIONS INC 123
- 12.8.1 COMPANY OVERVIEW 123
- 12.8.2 FINANCIAL OVERVIEW 123
- 12.8.3 PRODUCTS/SERVICES OFFERED 124
- 12.8.4 KEY DEVELOPMENTS 124
- 12.8.5 SWOT ANALYSIS 125
- 12.8.6 KEY STRATEGIES 125
12.9 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD 126
- 12.9.1 COMPANY OVERVIEW 126
- 12.9.2 FINANCIAL OVERVIEW 126
- 12.9.3 PRODUCTS/SERVICES OFFERED 126
- 12.9.4 KEY DEVELOPMENTS 126
- 12.9.5 SWOT ANALYSIS 127
- 12.9.6 KEY STRATEGIES 127
12.10 PARAGONIX TECHNOLOGIES, INC. 128
- 12.10.1 COMPANY OVERVIEW 128
- 12.10.2 FINANCIAL OVERVIEW 128
- 12.10.3 PRODUCTS/SERVICES OFFERED 128
- 12.10.4 KEY DEVELOPMENTS 128
- 12.10.5 SWOT ANALYSIS 129
- 12.10.6 KEY STRATEGIES 129

12.11 WATERS MEDICAL SYSTEMS 130
- 12.11.1 COMPANY OVERVIEW 130
- 12.11.2 FINANCIAL OVERVIEW 130
- 12.11.3 PRODUCTS/SERVICES OFFERED 130
- 12.11.4 KEY DEVELOPMENTS 130
- 12.11.5 SWOT ANALYSIS 131
- 12.11.6 KEY STRATEGIES 131

13 APPENDIX 132

13.1 REFERENCES 132
13.2 RELATED REPORTS 132